Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial
Edward A. Weinstein, Roger Paredes, Annie Gardner, Mary Almas, Mary Lynn Baniecki, Shunjie Guan, Elena Tudone, Simone Antonucci, Kevin Gregg, Carolina García‐Vidal, Adrián Camacho-Ortíz, Wayne Wisemandle, Steven G. Terra, Sean Liu, Judith A. Aberg, Meenakshi Rana, Lawrence Corey, Emily S. Ford, Jennifer Hammond, James M. Rusnak
Topics & Concepts
RitonavirPlaceboMedicineCoronavirus disease 2019 (COVID-19)EPICDouble blindInternal medicineClinical trialOncologyHuman immunodeficiency virus (HIV)VirologyAntiretroviral therapyViral loadAlternative medicinePathologyLiteratureDiseaseArtInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19